CCR2 and Huntington disease: Macrophages from HD patients in the late stage of the disease, displayed changes in the expression of surface markers in favour of anti-inflammatory M2 phenotype - high frequency of CCR2-CX3CR1+ cells – and low percentage of CCR2+CX3CR1- cells (Figure 3B).